- Acumen Powered by Robins Kaplan LLP®
- Affirmative Recovery
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Commercial/Project Finance and Real Estate
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Telecommunications Litigation and Arbitration
- Wealth Planning, Administration, and Disputes
Acumen Powered by Robins Kaplan LLP®
Ediscovery, Applied Science and Economics, and Litigation Support Solutions
-
June 1, 2022Chambers USA Recognizes Five Robins Kaplan Practice Groups And 17 Lawyers In 2022 Guide
-
June 1, 2022Seasoned Attorney Joins Firm’s Business Litigation Group
-
May 26, 2022Shira Shapiro Named Woman of Promise By The Pearl Society
-
June 3, 202219th Annual Advanced Insurance Law
-
June 9, 2022Building Your Brand: Perspectives and Insights from a Diverse Bar
-
June 10, 2022LGBTQ Legal Services: Transgender Name Change Clinic
-
May 24, 2022Briefly: Seeking Fees and Costs While on Appeal
-
May 19, 202211th Circ. Ban On Service Awards May Inhibit Class Actions
-
May 13, 2022Trademark Applications and the Murky Waters of Subject Matter Jurisdiction
-
June 2, 2022Sandberg Stepping Down as Meta COO After 14 Years
-
June 1, 2022Markets Revert to Recent Form as Pessimism Takes Hold
-
May 27, 2022Unexpectedly Strong Retail Sales Pull Markets Back from the Brink
Find additional firm contact information for press inquiries.
Find resources to help navigate legal and business complexities.
Read our attorneys' take on the latest news and trends in the legal and business industries.
ANDA Litigation Settlements
Fall 2017
| Case Name | Drug | Patent No(s). | Publicly Available Terms |
|---|---|---|---|
| Vivus Inc. v. Actavis Labs. FL Inc., 14-3786 (D.N.J.) | Qsymia® (phentermine / topiramate) | 7,056,890
7,553,818 7,659,256 7,674,776 8,580,298 8,580,299 |
Actavis to start selling its generic product on Dec. 1, 2024, or earlier “under certain circumstances.” Should Actavis begin selling a generic before its 2024 deadline, Vivus will collect royalties. |
| Eli Lilly and Co. v. Actavis Labs. UT Inc., 16-1119 (E.D. Va.) | Cialis® (tadalafil tablets) | 6,943,166 | Eli Lilly retains exclusivity over Cialis market until at least Sept. 27, 2018. Eli Lilly and generic defendants entered into a royalty-bearing license agreement. |
| Purdue Pharma L.P. v. Mylan Pharms. Inc., 15-1155 (D. Del.) | OxyContin® (oxycodone HCl extended-release tablets) | 9,073,933 | N/A |
| Amgen v. Apotex Inc., 16-0926 (D. Del.) | Sensipar® (cinacalcet tablets) | 9,375,405 | N/A |
| Amgen Inc. v. Micro Labs Ltd., 16-0854 (D. Del.) | Sensipar® (cinacalcet tablets) | 9,375,405 | N/A |
| AstraZeneca Pharms. LP v. Amneal Pharms. LLC, 15-1139 (D. Del.) | Byetta® (exenatide for injection) | 6,872,700 6,902,744 |
N/A |
| AstraZeneca AB v. Torrent Pharma Inc., 15-3375 (D.N.J.) | Daliresp® (roflumilast tablets) | 5,712,298 8,536,206 8,604,064 8,618,142 |
N/A |
GENERICally Speaking Fall 2017
Related Publications
First Quarter
ANDA Litigation Settlements
GENERICally Speaking Hatch Waxman Bulletin
First Quarter
New ANDA Cases
GENERICally Speaking Hatch Waxman Bulletin
First Quarter
ANDA Approvals
GENERICally Speaking Hatch Waxman Bulletin
First Quarter
Generic Launches
GENERICally Speaking Hatch Waxman Bulletin
March 22, 2022
Genentech, Inc. v. Sandoz, Inc.
GENERICally Speaking Hatch Waxman Bulletin
Related News
August 2, 2021
Back to Top
Any information that you send us in an e-mail message should not be confidential or otherwise privileged information. Sending us an e-mail message will not make you a client of Robins Kaplan LLP. We do not accept representation until we have had an opportunity to evaluate your matter, including but not limited to an ethical evaluation of whether we are in a conflict position to represent you. Accordingly, the information you provide to us in an e-mail should not be information for which you would have an expectation of confidentiality.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.